Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

18P - PARP1 trapping and hyperactivation by the decoy agonist OX425 induces DNA repair abrogation and a robust anti-tumor immune response


06 Mar 2023


Cocktail & Poster Display session


Vlada Zakharova


Annals of Oncology (2023) 8 (1suppl_2): 100901-100901. 10.1016/esmoop/esmoop100901


V. Zakharova1, C. Galassi2, N. Bloy2, C. Doizelet1, V. Hayes1, L. Galluzzi2, W. Jdey1

Author affiliations

  • 1 R&d, Onxeo, 75015 - Paris/FR
  • 2 Department Of Radiation Oncology, Weill Cornell Medical College, 10065 - New York/US


This content is available to ESMO members and event participants.

Abstract 18P


Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) lead to synthetic lethality when used in cancers with homologous recombination deficiency (HRD). Despite clinical benefits of PARPi, this treatment is associated with the development of resistance of HRD tumors. Here, we describe the anticancer effects of OX425, a first-in-class oligodeoxynucleotide that operates as a PARP1 decoy, resulting in constitutive PARP1 hyperactivation and consequent exhaustion of the DNA damage response.


OX425-induced PARP trapping, hyperactivation and cell cytotoxicity were examined in vitro in HRD and homologous recombination proficient (HRP) human cancer cells, as well as in non-transformed cell lines. DNA repair efficacy was monitored by analyzing repair protein recruitment to damage sites. RNAseq analysis in HRP/HRD tumor cells treated with OX425 or PARP inhibitors was employed to uncover the molecular mechanisms underlying OX425 effects. The anticancer efficacy of OX425 was assessed in vivo in different HRD and HRP tumor models, including endogenous mammary carcinomas as driven in immunocompetent female mice by MPA plus DMBA.


At odds with conventional PARP inhibitors, OX425 bound to and hyperactivated PARP1 with high affinity in a dose-dependent manner, resulting in elevated cytotoxicity to multiple cancer cells with slight benefits to HRD cancers. Moreover, long-term treatment with OX425 did not show any mutagenicity compared to PARPi. The activity of OX425 was specific to tumor cells, as no significant effect on cell viability was observed for normal cells, at odds with PARP inhibitors. In line with in vitro results, OX425 mediated considerable anticancer effects in vivo as it generated an immunologically active tumor microenvironment. Importantly, OX425 treatment significantly delayed acquired resistance to olaparib in BRCA1 mutated MDA-MB-436 cell-derived xenografts.


Our results provide a safety profile and preclinical rationale for using OX425 in patients bearing HRD tumors, to trigger DNA damage exhaustion and initiate inflammatory responses in the tumor microenvironment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.




V. Zakharova, C. Doizelet, V. Hayes, W. Jdey: Financial Interests, Institutional, Full or part-time Employment: onxeo. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.